Empowered Funds LLC Invests $1.79 Million in Puma Biotechnology, Inc. $PBYI

Empowered Funds LLC bought a new position in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 220,316 shares of the biopharmaceutical company’s stock, valued at approximately $1,787,000.

Other institutional investors have also bought and sold shares of the company. BlackRock Inc. bought a new stake in Puma Biotechnology in the second quarter valued at $30,856,000. Russell Investments Group Ltd. lifted its holdings in shares of Puma Biotechnology by 4,823,365.0% during the third quarter. Russell Investments Group Ltd. now owns 964,693 shares of the biopharmaceutical company’s stock valued at $5,123,000 after acquiring an additional 964,673 shares during the period. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Puma Biotechnology during the second quarter valued at $5,214,000. Goldman Sachs Group Inc. boosted its stake in shares of Puma Biotechnology by 238.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 793,962 shares of the biopharmaceutical company’s stock valued at $4,724,000 after purchasing an additional 559,345 shares in the last quarter. Finally, AQR Capital Management LLC boosted its stake in shares of Puma Biotechnology by 410.1% in the 4th quarter. AQR Capital Management LLC now owns 666,605 shares of the biopharmaceutical company’s stock valued at $3,966,000 after purchasing an additional 535,933 shares in the last quarter. Institutional investors and hedge funds own 61.29% of the company’s stock.

Insider Buying and Selling

In related news, Director Adrian Senderowicz sold 27,000 shares of Puma Biotechnology stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $7.20, for a total value of $194,400.00. Following the completion of the transaction, the director directly owned 27,000 shares of the company’s stock, valued at $194,400. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Douglas Hunt sold 8,460 shares of the company’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $8.26, for a total transaction of $69,879.60. Following the transaction, the insider owned 196,841 shares in the company, valued at approximately $1,625,906.66. This trade represents a 4.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 132,028 shares of company stock valued at $1,006,711 in the last 90 days. 22.20% of the stock is owned by corporate insiders.

Key Headlines Impacting Puma Biotechnology

Here are the key news stories impacting Puma Biotechnology this week:

• Positive Sentiment: Zacks raised its fiscal 2026 EPS forecast to $0.37 from $0.31, above the current full-year consensus of $0.31. It also increased its fiscal 2028 estimate to $0.45 from $0.42, signaling improved expectations for near- and longer-term profitability.
• Positive Sentiment: Quarterly estimates for the first and second quarters of 2027 were lifted to $0.04 and $0.07, respectively, from $0.03 and $0.06.
• Neutral Sentiment: The current full-year consensus EPS estimate remains at $0.31, indicating that the revisions have not yet changed the broader market outlook for the company’s current fiscal year.
• Negative Sentiment: Zacks cut its fiscal 2027 EPS forecast to $0.14 from $0.18. It also lowered fourth-quarter 2027 EPS to $0.02 from $0.04 and third-quarter 2027 EPS to $0.02 from $0.05.
• Negative Sentiment: The third-quarter 2026 EPS estimate was reduced to $0.06 from $0.08, suggesting softer near-term earnings expectations.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. TD Cowen increased their target price on shares of Puma Biotechnology from $5.00 to $6.00 and gave the stock a “hold” rating in a research report on Friday, August 7th. Weiss Ratings upgraded shares of Puma Biotechnology from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, August 21st. Finally, Wall Street Zen upgraded shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 15th. Two research analysts have rated the stock with a Hold rating, According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $6.00.

Puma Biotechnology Price Performance

PBYI stock opened at $9.41 on Friday. The business has a fifty day moving average price of $8.50 and a 200 day moving average price of $7.51. Puma Biotechnology, Inc. has a fifty-two week low of $4.30 and a fifty-two week high of $9.73. The stock has a market capitalization of $485.74 million, a price-to-earnings ratio of 18.10 and a beta of 1.24.

Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $0.19 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.15. The company had revenue of $56.50 million for the quarter, compared to analyst estimates of $53.00 million. Puma Biotechnology had a return on equity of 20.76% and a net margin of 11.50%. On average, equities analysts expect that Puma Biotechnology, Inc. will post 0.37 earnings per share for the current fiscal year.

Puma Biotechnology Profile

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.